Fig. 3: Further outcomes for infused cohort (n = 125).

a Probability of remaining in B-cell aplasia. Main events are B-cell recovery or CD19 positive relapse, competing events are non-response, disease emergence other than CD19 positive and death. b Cumulative incidence of relapse. Death in remission and non-response are competing events. All documented relapses were considered, i.e. including those occurring after MRD emergence and/or other therapy following CAR T. This is because censoring further treatments received after CAR T would underestimate the true incidence of relapse after tisagenlecleucel infusion. c Cumulative incidence of relapse stratified by immunophenotype. Competing events non-response, death in remission, myeloid switch and relapse with unknown immunophenotype.